Back

High rates of discontinuation and reinitiation of secondary preventive medications after a first myocardial infarction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention (1) Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ali Yari

Karolinska Institute, Stockholm (Sweden)

7 More presentations in this session

Presentation thumbnail
Incidence of metabolic syndrome and its association with hs-CRP and RC levels in a large cohort study
Associate Professor L. Bikdelu (Mashhad, IR)
Abstract Slides Video
Presentation thumbnail
Changing trends in myocardial infarction mortality among young adults in the United States: a 25-year analysis of disparities and the COVID-19 impact
Doctor N. Abou Khater (Abu Dhabi, AE)
Abstract Slides Video
Presentation thumbnail
THe Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): access to care
Doctor J. Hahnle (Cape Town, ZA)
Abstract Slides Video
Presentation thumbnail
Development of a multidimensional data-driven prediction model and risk stratification for 1-year cardiac mortality in AMI patients
Professor J. Wu (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Herpes zoster vaccine effectiveness against cardiovascular events - a systematic literature review and meta-analysis
Doctor C. Williams (Wavre, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study
thumbnail
Congress Presentation
The effect of discontinuing long-term beta-blockers following acute myocardial infarction in optimally treated, stable patients without heart failure - a Danish, nationwide cohort study
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources